HC Wainwright Reiterates Buy Rating for Valneva (NASDAQ:VALN)

HC Wainwright reiterated their buy rating on shares of Valneva (NASDAQ:VALN - Free Report) in a report issued on Wednesday, Benzinga reports. They currently have a $26.00 target price on the stock.

Separately, Guggenheim dropped their price target on Valneva from $18.00 to $17.00 and set a buy rating on the stock in a research report on Friday, March 22nd.

Valneva Stock Performance

Shares of VALN traded down $0.26 during midday trading on Wednesday, reaching $7.24. 19,120 shares of the stock were exchanged, compared to its average volume of 11,216. The company has a market capitalization of $504.19 million, a price-to-earnings ratio of -4.75 and a beta of 2.22. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.65 and a quick ratio of 1.37. Valneva has a twelve month low of $6.58 and a twelve month high of $17.05. The business's 50-day moving average price is $7.68 and its 200 day moving average price is $9.29.

Valneva (NASDAQ:VALN - Get Free Report) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of $0.20 by ($0.70). The firm had revenue of $45.12 million during the quarter, compared to analyst estimates of $45.06 million. Valneva had a negative net margin of 65.99% and a negative return on equity of 59.48%. On average, sell-side analysts expect that Valneva will post 0.11 EPS for the current fiscal year.

Institutional Trading of Valneva

A hedge fund recently raised its stake in Valneva stock. General American Investors Co. Inc. lifted its position in shares of Valneva SE (NASDAQ:VALN - Free Report) by 2.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 354,361 shares of the company's stock after acquiring an additional 9,361 shares during the quarter. General American Investors Co. Inc. owned 0.51% of Valneva worth $2,831,000 at the end of the most recent quarter. 11.39% of the stock is owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.